Inlyta (axitinib)

P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026

This study proposes a robust 12-lncRNA signature linking cuproptosis and oxidative stress with prognosis and therapy response in ovarian cancer, offering preliminary insights for personalized treatment guidance.

In summary, the findings of the study indicate that elevated FSTL1 expression could serve as a prognostic biomarker for unfavorable outcomes in colorectal cancer (CRC) diagnosis and may also identify potential targets for immunotherapy in CRC.

P2, N=260, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=120 --> 260

P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026

While conventional chemotherapy and immune checkpoint inhibitors remain largely ineffective, advances in ACC biology have driven the development of mechanism-based treatments. Future trials should prioritize biomarker-guided patient selection, rational combinations, and integration of molecular diagnostics to improve outcomes in this indolent but ultimately fatal disease.

In our work, we investigated the mechanism by which NUMBL facilitates VM-mediated resistance at the molecular, cellular, human tissue, and animal levels. By integrating novel insights into the roles of NUMBL, VM, and deubiquitination, this research aims to establish a theoretical framework for elucidating the underlying mechanisms of axitinib resistance and provide new perspectives for improving the efficacy of axitinib in the treatment of ccRCC.

P=N/A, N=40, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital

P1/2, N=98, Active, not recruiting, Fox Chase Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Apr 2025 --> Apr 2026

In this study, skeletal muscle (C2C12) preparations were separately treated with small-molecule tyrosine kinase inhibitors; imatinib, dasatinib, axitinib, and erlotinib for 24 h. Thereafter, the effect of the test drugs was assessed on cell viability using the MTT assay, while glucose uptake was determined by measuring residual glucose concentrations in the culture medium with a glucometer. Dasatinib shows promising potential with regard to antidiabetic capabilities. Further research is needed to better understand SMKI effects on metabolic homeostasis, which can perhaps inform future therapeutic strategies.

PRKD2 integrates secretory stress, stem-like programmes and immune evasion, driving aggressive MM yet exposing a vulnerability to VEGFR/PDGFR blockade. Direct PRKD2 targeting or axitinib-based combinations-including proteasome inhibition-deserve clinical evaluation for high-risk MM.

Postpartum staging demonstrated multiple pulmonary metastases, and systemic therapy was initiated with cabozantinib plus nivolumab. Despite temporary stabilization, disease progression occurred, and subsequent lines of therapy included axitinib, everolimus, and sunitinib...The rare occurrence of breast metastasis highlights the potential for unusual dissemination patterns in RCC. Reporting such uncommon cases contributes to improved understanding of disease behavior, helps guide clinical decision-making, and emphasizes the importance of individualized, multidisciplinary management in this challenging setting.